Skip to content

Serotonin: all studies

Page 182 of 400: studies 1,811 to 1,820 of 3,999, newest first. Back to the serotonin overview

Research

Changes in neuroticism and values after naturalistic use of psychedelics and MDMA: a prospective survey study

Journal of Affective Disorders Reports July 1, 2026 Abigail E. Calder, Vincent J Diehl, Bernd Hinney et al.

Background Serotonergic psychedelics and MDMA may improve mental health through reductions in neuroticism and changes in personal values. While decreases in neuroticism following serotonergic psychedelics are sometimes observed, it is unclear which facets of neuroticism respond the most, and MDMA remains understudied. People also report value shifts after psychedelic experiences, but...

DOI: 10.1016/j.jadr.2026.101127 (opens in new tab) Neuroticism Survey research Personality Naturalistic observation +3

A critical review of brain entropy as a biomarker of the psychedelic state.

Neuroscience & Biobehavioral Reviews July 1, 2026 Bruno Moses, Manoj K. Doss, Enzo Tagliazucchi 1 citation

Serotonergic psychedelics induce profound alterations in consciousness, giving rise to an altered state commonly referred to as the psychedelic state. The entropic brain hypothesis proposes that brain entropy (i.e., the degree of uncertainty in the distribution of brain states) is elevated during the psychedelic state, as well as in other states characterized by an expanded breadth of...

Neuroestimulantes naturales: de rituales ancestrales a terapias de vanguardia

Revista CienciaUANL July 1, 2026 Armando Ordaz‐hernández, M. Corona-Ramírez, Israel Jesús Orlando Guerrero

La psilocibina, presente en los “hongos mágicos”, y la 5-MeO-DMT, secretada por el sapo Incilius alvarius, fueron empleadas ancestralmente en rituales espirituales en México. Hoy, la ciencia las reconoce como terapias prometedoras contra depresión, ansiedad, estrés postraumático y adicciones resistentes a tratamientos convencionales. Actúan sobre receptores de serotonina y estimulan la...

DOI: 10.29105/cienciauanl29.138-5 (opens in new tab) Addiction Mental health Clinical practice Psychotherapist

Convergent biosynthesis of psilocybin in an ectomycorrhizal lineage: is the psychoactive end-product the selected trait?

EcoEvoRxiv July 1, 2026 Mellica Askari, Varun Surapaneni preprint

The fungivore-deterrence hypothesis, that psilocybin evolved as a chemical defence against arthropod fungivores via 5-HT receptor agonism, has become the working consensus in fungal chemical ecology, despite resting on a phylogenomic pattern of horizontal gene transfer among saprotrophs and remarkably little direct experimental evidence. Recent biochemistry shows that the ectomycorrhizal...

Psychedelics in treatment-resistant depression: a comprehensive review of mechanisms, clinical evidence, and recommendations.

Neuropsychiatrie June 30, 2026 Cielo A Estela-Fernandez, Reem Mohamed Yousif Elsheikh, Dal Bianco Beatrice et al.

Major depressive disorder (MDD) is a heterogeneous, debilitating disorder. A distinct subgroup within the MDD spectrum is identified to have treatment-resistant depression (TRD). There is an impetus to find alternative treatments for TRD to reduce disease burden and improve quality of life. Psychedelics have been used in the treatment of various psychiatric disorders since the 1950s, with...

Chronic psilocin microdosing produces limited behavioral effects and does not enhance neurogenesis in rats.

Pharmacology, Biochemistry, and Behavior June 30, 2026 Lucie Ladislavová, Viera Kútna, Kristýna Mazochová et al.

Psilocin (4-hydroxy-N, N-dimethyltryptamine) is a substituted tryptamine alkaloid and a nonselective serotonergic agonist acting predominantly at 5-HT2A/C receptors, with substantial binding to 5-HT1A and 5-HT2B receptors. Microdosing is the practice of taking a very small, sub-perceptual dose, typically 5% to 10% of a full recreational dose, to improve mood, creativity, and focus without...

Intrinsic excitation-inhibition imbalance in major depressive disorder.

Journal of Affective Disorders June 29, 2026 Yao Ge, Lijuan Chen, Yu Shen et al.

Major depressive disorder (MDD) ranks among the foremost contributors to disability worldwide, yet its neurophysiological mechanisms remain poorly understood. Excitation-inhibition (E/I) imbalance has been implicated in MDD pathophysiology, but cortex-wide E/I ratio and its molecular substrates in MDD remain unknown. Resting-state functional magnetic resonance imaging data from 254 MDD patients...

Classical psychedelic microdosing, mood, and cognitive function: An umbrella review with narrative synthesis

Journal of Psychopharmacology June 28, 2026 Yiğit Özaydın, Buket Canlan Özaydın

Background: Psychedelic microdosing—repeated sub-perceptual doses of lysergic acid diethylamide (LSD) or psilocybin—has attracted scientific interest as a potential mood and cognitive intervention. The evidence base remains methodologically heterogeneous and vulnerable to expectancy bias. Methods: We conducted an umbrella review with narrative synthesis following Joanna Briggs Institute...

Pivotal physical states: The somatic equivalent to pivotal mental states

Journal of Psychedelic Studies June 26, 2026 Malin V. Uthaug, Jack G. Allocca, Martha N. Havenith et al.

Abstract Background The Pivotal Mental States (PiMS) construct posits that psychedelics and other stress-inducing practices, such as fasting and hypoxia, can evoke transformative mental states through increased serotonin receptor activation in the brain. These states are associated with enhanced cognitive flexibility, accelerated associative learning, and psychological insights that may...

DOI: 10.1556/2054.2026.00482 (opens in new tab) Construct python library Action physics Transformative learning Cognition +7

The intersection between psychedelics and schizophrenia spectrum disorders: Reevaluating risk and therapeutic potential.

Journal of Psychopharmacology June 25, 2026 Pavan S Brar, Rebecca B Price, Stephen Ross et al.

In the past decade, interest in studying psychedelic compounds as potential therapeutic agents has resurged. These studies carefully exclude individuals at risk for developing psychotic symptoms in response to psychedelic use. Given the potential for psychedelics to be established as treatments in psychiatry, it is important to more robustly understand their link with psychosis and...